昊海生物科技(06826)发布公告，于2025年12月12日，该公司斥资112.38万港元回购4.23万股。 ...

格隆汇12月12日丨昊海生物科技(06826.HK)发布公告，2025年12月12日耗资112.4万港元回购4.2万股， 回购价格每股26.5-26.64港元。 ...

智通财经APP讯，昊海生物科技(06826)发布公告，于2025年12月12日，该公司斥资112.38万港元回购 4.23万股。 ...

FF305 翌日披露報表 (股份發行人 ── 已發行股份或庫存股份變動、股份購回及/或在場内出售庫存股份) 表格類別： 股票 狀態： 新提交 公司名稱： 上海昊海生物科技股份有限公司（於中華人民共和國註冊成立的股份有限公司） 呈交日期： 2025年12月12日 FF305 第 3 頁 共 10 頁 v 1.3.0 如上市發行人的已發行股份或庫存股份出現變動而須根據《香港聯合交易所有限公司（「香港聯交所」）證券上市規則》(「《主板上市規則》」)第13.25A條 / 《香港聯合交易所有限公司GEM證券 上市規則》(「《GEM上市規則》」)第17.27A條作出披露，必須填妥第一章節 。 | 第一章節 | | | | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | | 1. 股份分類 | 普通股 | 股份類別 H | | | 於香港聯交所上市 | 是 | | | 證券代號 (如上市) | 06826 | 說明 H 股 | | | | | | | A. 已發行股份或庫存股份變動 | | | | | | | | | | | 已發行股份（不包括庫存股份）變 ...

Core Viewpoint - The company has approved the use of temporarily idle raised funds for cash management, allowing up to RMB 300 million for investment in safe and liquid financial products, ensuring that it does not affect the normal investment plans of the raised funds [1] Group 1: Cash Management Approval - The company convened its sixth board meeting on November 7, 2025, and approved the proposal to use temporarily idle raised funds for cash management [1] - The maximum amount for cash management is set at RMB 300 million, which can be used for investments in secure and liquid products such as time deposits and certificates of deposit [1] - The investment period is valid for 12 months from the date of board approval, and the funds can be used in a rolling manner within the specified limits [1] Group 2: Special Settlement Account - The company has opened a special settlement account for cash management products to facilitate the management of raised funds [2] - The account will be used exclusively for the settlement of temporarily idle raised funds and will not be used for non-raised funds or other purposes [2] - The account will be closed promptly when cash management products mature and there are no further purchase plans [2] Group 3: Risk Control Measures - The finance department will analyze and monitor the investment direction and project progress of bank cash management products, taking timely protective measures if adverse factors are identified [2] - The audit committee and independent directors have the authority to supervise and inspect the use of funds, and may hire professional institutions for auditing if necessary [2] - The company will strictly adhere to relevant regulations and timely fulfill information disclosure obligations [2] Group 4: Impact on the Company - The establishment of the special settlement account and the planned use of idle raised funds for cash management will not affect the implementation of investment projects or the safety of raised funds [3] - The cash management of temporarily idle funds is expected to generate investment returns, which will enhance the overall performance of the company and provide better returns for shareholders [3]

FF305 翌日披露報表 (股份發行人 ── 已發行股份或庫存股份變動、股份購回及/或在場内出售庫存股份) 表格類別： 股票 狀態： 新提交 公司名稱： 上海昊海生物科技股份有限公司（於中華人民共和國註冊成立的股份有限公司） 呈交日期： 2025年12月11日 如上市發行人的已發行股份或庫存股份出現變動而須根據《香港聯合交易所有限公司（「香港聯交所」）證券上市規則》(「《主板上市規則》」)第13.25A條 / 《香港聯合交易所有限公司GEM證券 上市規則》(「《GEM上市規則》」)第17.27A條作出披露，必須填妥第一章節 。 | 第一章節 | | | | | | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 1. 股份分類 | 普通股 | 股份類別 H | | | | 於香港聯交所上市 | 是 | | | | 證券代號 (如上市) | 06826 | 說明 | H 股 | | | | | | | | A. 已發行股份或庫存股份變動 | | | | | | | | | | | | | 已發行股份（不包括庫存股份） ...

格隆汇12月11日丨昊海生物科技(06826.HK)发布公告，2025年12月11日耗资135.64万港元回购5.1万股， 回购价格每股26.5-26.66港元。 昊海生物科技(06826.HK)12月11日耗资135.64万港元回购5.1万股 昊海生物科技(06826.HK)12月10日耗资 97.93万港元回购3.65万股 相关事件 ...

智通财经APP讯，昊海生物科技(06826)发布公告，于2025年12月11日，该公司斥资135.64万港元回购5.1 万股股份，每股回购价格为26.5-26.66港元。 ...

FF305 翌日披露報表 (股份發行人 ── 已發行股份或庫存股份變動、股份購回及/或在場内出售庫存股份) 表格類別： 股票 狀態： 新提交 公司名稱： 上海昊海生物科技股份有限公司（於中華人民共和國註冊成立的股份有限公司） 呈交日期： 2025年12月11日 如上市發行人的已發行股份或庫存股份出現變動而須根據《香港聯合交易所有限公司（「香港聯交所」）證券上市規則》(「《主板上市規則》」)第13.25A條 / 《香港聯合交易所有限公司GEM證券 上市規則》(「《GEM上市規則》」)第17.27A條作出披露，必須填妥第一章節 。 | 第一章節 | | | | | | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 1. 股份分類 | 普通股 | 股份類別 H | | | | 於香港聯交所上市 | 是 | | | | 證券代號 (如上市) | 06826 | 說明 | H 股 | | | | | | | | A. 已發行股份或庫存股份變動 | | | | | | | | | | | | | 已發行股份（不包括庫存股份） ...

Group 1 - The company, Haohai Biological Technology, announced the convening of its sixth board meeting on November 7, 2025, to review a proposal for cash management using temporarily idle raised funds [2] - The board approved the use of up to RMB 300 million (including principal) of temporarily idle raised funds for cash management, ensuring that it does not affect the normal investment plans of the raised funds [2] - The cash management will involve purchasing investment products that are safe, liquid, and have capital protection agreements, including but not limited to agreement deposits, notice deposits, time deposits, large certificates of deposit, and income certificates [2]